Home / Drug shortages / Tobramycin Sulfate Injection

Tobramycin Sulfate Injection — FDA Drug Shortage

To Be Discontinued — Hospira, Inc., a Pfizer Company

The FDA lists a drug shortage record for Tobramycin Sulfate Injection (injection) from Hospira, Inc., a Pfizer Company with status To Be Discontinued. The shortage was first posted on 07/17/2026.

Shortage Details

Status
To Be Discontinued
Company
Hospira, Inc., a Pfizer Company
Package NDC
0409-3578-01
Dosage Form
Injection
Presentation
Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)
Initial Posting
07/17/2026
Revised Date

FDA data resources